Gilead and Arcus Establish 10-Year Next-Generation Cancer Immunotherapy Partnership; Options Exercised
Gilead Sciences and Arcus Biosciences entered into a 10-year partnership to co-develop and co-commercialize all current and future therapeutic product candidates in Arcus’s pipeline.
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.